- Reaction score
- 8,251
I am new to the site so if this was talked about else where forgive me..
I was reading an article about the Vixen company and the JaKs inhibitor with the rats (I'm assuming thats is old news here) anyway they went on in the article about this researcher in France. I cut and pasted below from the article
'One treatment about to enter clinical testing is low-dose IL-2. In a 2014 study, dermatologist Thierry Passeron and colleagues at the University Hospital of Nice, France, reported statistically significant hair regrowth in four of five patients — each of whom had long-standing, treatment-resistant disease — who were given a four-week course of low-dose IL-2 injections[3]. These results weren’t as celebrated as Christiano and colleagues’ findings because, by Passeron’s own admission, “although two patients had more than 50% regrowth, two had regrowth that wasn’t enough to stop them wearing a wig”.
Two years on and the trial participants, as well as Passeron, are looking back on the trial more favourably. “We have had no relapses,” says Passeron, “even though treatment stopped after the trial.” Not only did the participants not relapse, but their hair continued to regrow: the two women who still had to wear wigs now have almost complete regrowth; of the others, one has almost complete regrowth and the other has more than 75% regrowth. “I’ve never seen such a result — we included very severe patients who had failed up to three types of treatment before and they responded,” he says. But, he warns, there may have been a strong placebo effect since people came to hospital for injections for four weeks.
To test the treatment, with funding from the Programme Hospitalier Recherche Clinique (PHRC), Passeron and colleagues are doing a prospective, placebo-controlled randomised trial in 80 patients around France and following them up for one year. They will take blood samples to test a hypotheses supported by biopsies from the five patients in the 2014 open-label study: that the low-dose IL-2 stimulates the activity of T regulator cells that dampen down the damaging T effector cells and reduce the immune infiltrate around the hair follicle. “If our hypothesis is true, and the result is good,” says Passerine, “then, with the impressive JAK inhibitors, I’m hopeful in the coming years that the situation for alopecia patients will improve.”
Do you guys know anything about him and his research trial? I tried to look him up but found very little in English and nothing that was after the trial and what the results were.
I was reading an article about the Vixen company and the JaKs inhibitor with the rats (I'm assuming thats is old news here) anyway they went on in the article about this researcher in France. I cut and pasted below from the article
'One treatment about to enter clinical testing is low-dose IL-2. In a 2014 study, dermatologist Thierry Passeron and colleagues at the University Hospital of Nice, France, reported statistically significant hair regrowth in four of five patients — each of whom had long-standing, treatment-resistant disease — who were given a four-week course of low-dose IL-2 injections[3]. These results weren’t as celebrated as Christiano and colleagues’ findings because, by Passeron’s own admission, “although two patients had more than 50% regrowth, two had regrowth that wasn’t enough to stop them wearing a wig”.
Two years on and the trial participants, as well as Passeron, are looking back on the trial more favourably. “We have had no relapses,” says Passeron, “even though treatment stopped after the trial.” Not only did the participants not relapse, but their hair continued to regrow: the two women who still had to wear wigs now have almost complete regrowth; of the others, one has almost complete regrowth and the other has more than 75% regrowth. “I’ve never seen such a result — we included very severe patients who had failed up to three types of treatment before and they responded,” he says. But, he warns, there may have been a strong placebo effect since people came to hospital for injections for four weeks.
To test the treatment, with funding from the Programme Hospitalier Recherche Clinique (PHRC), Passeron and colleagues are doing a prospective, placebo-controlled randomised trial in 80 patients around France and following them up for one year. They will take blood samples to test a hypotheses supported by biopsies from the five patients in the 2014 open-label study: that the low-dose IL-2 stimulates the activity of T regulator cells that dampen down the damaging T effector cells and reduce the immune infiltrate around the hair follicle. “If our hypothesis is true, and the result is good,” says Passerine, “then, with the impressive JAK inhibitors, I’m hopeful in the coming years that the situation for alopecia patients will improve.”
Do you guys know anything about him and his research trial? I tried to look him up but found very little in English and nothing that was after the trial and what the results were.
